Cris Kamperschroer Selected Research

PF-06671008

1/2022	A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.
1/2019	A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cris Kamperschroer Research Topics

Disease

11	Neoplasms (Cancer) 01/2022 - 10/2012
4	Infections 01/2016 - 07/2002
3	Human Influenza (Influenza) 10/2010 - 06/2006
2	Cytokine Release Syndrome 12/2020 - 11/2019
2	Lymphoma (Lymphomas) 01/2016 - 01/2012
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2012 - 07/2006
1	Hypophosphatemia 01/2022
1	Hypersensitivity (Allergy) 02/2021
1	Colonic Neoplasms (Colon Cancer) 10/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2020
1	Inflammation (Inflammations) 12/2019
1	Multiple Myeloma 11/2019
1	Stillbirth 06/2015
1	Virus Diseases (Viral Diseases) 01/2014
1	Bacterial Infections (Bacterial Infection) 01/2009
1	Wasting Syndrome (Wasting Disease) 07/2002

Drug/Important Bio-Agent (IBA)

5	CytokinesIBA 02/2021 - 07/2002
4	AntigensIBA 12/2020 - 10/2010
4	Proteins (Proteins, Gene)FDA Link 01/2016 - 06/2006
3	Cadherins (E-Cadherin)IBA 01/2022 - 01/2019
3	Pharmaceutical PreparationsIBA 02/2021 - 12/2019
2	PF-06671008IBA 01/2022 - 01/2019
2	VaccinesIBA 01/2009 - 06/2006
2	Antiviral Agents (Antivirals)IBA 10/2006 - 07/2002
2	Signaling Lymphocytic Activation Molecule Associated ProteinIBA 10/2006 - 07/2006
1	Cell Adhesion MoleculesIBA 01/2022
1	Antigen-Antibody Complex (Immune Complex)IBA 02/2021
1	Enterotoxin ReceptorsIBA 01/2020
1	crisamicin AIBA 11/2019
1	B-Cell Maturation AntigenIBA 11/2019
1	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 11/2019
1	trans-sodium crocetinate (crocetin)IBA 01/2019
1	tanezumabIBA 06/2015
1	Monoclonal AntibodiesIBA 10/2012
1	utomilumabIBA 10/2012
1	Biomarkers (Surrogate Marker)IBA 01/2012
1	Immunomodulating AgentsIBA 01/2012
1	Immunoglobulin G (IgG)IBA 10/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2002
1	Interleukin-6 (Interleukin 6)IBA 07/2002
1	Cytokine Receptors (Cytokine Receptor)IBA 07/2002
1	Interleukin-1 (Interleukin 1)IBA 07/2002

Therapy/Procedure

4	Therapeutics 01/2022 - 10/2012
2	Immunotherapy 10/2020 - 01/2020